Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (260)	1/31/2007 3:22:18 PM
From: Mike McFarland	Respond to of 360

A post on the yahoo thread, copied from a blog, said that he'd bought a position in PARS--and had become a bit of a shareholder advocate. Well, that might be too kind--to management 'gadfly' might be the word. On the other hand, maybe you have to respect a guy who puts that much money at stake on a company that has burned through $300M. Yes-- things should change. Arguably, shedding genomics and leaning out could be good enough and we don't need a big shakeup. But we have not seen any money out of the DR unit either yet. The cynical comment we saw on this thread awhile back about the expensive rats might be on target for all I know. Read the Melkinova article from two years ago-- the url is on my thread. Something to think about. There has got to be a viable business lurking somewhere under the pharmacogenomics tree. Low lying fruit--glgc is going for the dropped apples. I like that...my family used to gather drops for applesauce. (just thinking out loud and typing faster than I think...)

To: Steve Lokness who wrote (260)	2/5/2007 4:12:01 PM
From: Mike McFarland	Read Replies (2) \| Respond to of 360

OT Caliper (I saw you ask Tuck about CALP, fwiw:) Caliper has also begun to shift microfluidics into another field. “We’ve just entered an agreement to acquire Xenogen, whose technology uses luciferase to light up the inside of mice,” Hrusovsky reports. “We believe that by linking our innovative in vitro technologies like microfluidics to in vivo technologies, we can cross the in vitro–in vivo bridge and provide much needed platforms for drug discovery research. Ultimately we plan to go into models for human prediction.” sciencemag.org I added the emphasis.